A Phase 2 interventional study of LEO 90100 in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 10 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.
Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.
Among the 47 studies testing calcipotriene in Psoriasis, this one is the 33rd largest by enrollment, is one of 4 that started in 2012, is one of 9 in phase 2, and was the 23rd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 19 · Phase 4 12
First in 2004; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 200 across the 47 interventional studies. Of the 41 that completed or were terminated, 21 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 47 have an industry lead sponsor. The 10 most frequent:
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
79 studies in Psoriasis by LEO Pharma: 1 open now, 2 under way, none of them phase 3. Of 77 finished, 36 (47%) have results posted.
Among the 79 studies in Psoriasis by LEO Pharma, this one is the 42nd largest by enrollment of the 71 interventional ones that give a count, is one of 8 that started in 2012, is one of 24 in phase 2, and was the 36th registered.
LEO Pharma’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing calcipotriene in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among LEO Pharma’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
A Phase 2 Maximal Use Systemic Exposure (MUSE) study evaluating the safety and efficacy of LEO 90100 used once daily in subjects with extensive psoriasis vulgaris.
The purpose of the present study is to assess the systemic safety of LEO 90100. Although LEO 90100 contains the same active ingredients in the same concentration as DAIVOBET/DOVOBET/TACLONEX ointment, the degree of absorption of the active ingredients from the new formulation may differ. Systemic safety will be assessed through the effect of LEO 90100 on calcium metabolism and HPA axis function under maximum use conditions (i.e., in subjects with very extensive psoriasis on the trunk, limbs and scalp, using up to 120g per week of LEO 90100 for up to 4 weeks). Data from this study, together with the measurements of albumin-corrected serum calcium and the calcium:creatinine ratio in spot urine samples in the planned phase 2 and 3 studies in the development program for LEO 90100, are expected to provide adequate information with respect to the systemic safety of LEO 90100.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At SV2 and Day 0 (Visit 1), a clinical diagnosis of psoriasis vulgaris of at least 6 months duration involving the trunk and/or limbs and the scalp which is;
Exclusion Criteria:
Systemic treatment with biological therapies (whether marketed or not marketed), with a possible effect on psoriasis vulgaris within the following time period prior to Day 0 (Visit 1);
Any of the following conditions, whether known or suspected:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LEO 90100
Drug pages: Calcipotriene · Betamethasone dipropionate
Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate)
Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After Adrenocorticotrophic Hormone-challenge (ACTH-challenge)
HPA-axis testing by means of the rapid standard-dose cosyntropin test (ACTH-challenge test) for detection of adrenal suppression.
Time frame: Day 28
Change in Albumin-corrected Serum Calcium From Baseline to Day 28
The effect of LEO 90100 on calcium metabolism was evaluated based on change in albumin-corrected serum calcium from Baseline to Day 28.
Time frame: Baseline and Day 28
Change in 24-hour Urinary Calcium Excretion From Baseline to Day 28
The effect of LEO 90100 on calcium metabolism was evaluated based on change in 24-hour urinary calcium excretion from Baseline to Day 28 in 24-hour.
Time frame: Baseline and Day 28
Change in 24-hour Urinary Calcium:Creatinine Ratio From Baseline to Day 28
The effect of LEO 90100 on calcium metabolism was evaluated based on change in urinary calcium:creatinine ratio from Baseline to Day 28.
Time frame: Baseline and Day 28
Number of Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 and 60 Minutes After ACTH-challenge at Day 28
Serum cortisol concentrations at 30 and 60 minutes after injection were measured in order to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration is ≤18mcg/dl at 30 minutes after the injection.
Time frame: Day 28
Number of Participants With an Adverse Drug Reaction (ADR)
Adverse drug reactions (ADRs) were defined as adverse events for which the investigator has not described the causal relationship to investigational medication as "not related".
Time frame: Baseline to Day 28
Change in Serum Phosphate From Baseline to Day 28
The effect of LEO 90100 on calcium metabolism was evaluated based on change in serum phosphate from Baseline to Day 28.
Time frame: Baseline and Day 28
Change in 24-hour Urinary Phosphate Excretion From Baseline to Day 28
The effect of LEO 90100 on calcium metabolism was evaluated based on change in 24-hour urinary phosphate excretion from Baseline to Day 28.
Time frame: Baseline and Day 28
Change in Urinary Phosphate: Creatinine Ratio From Baseline to Day 28
The effect of LEO 90100 on calcium metabolism was evaluated based on change in urinary phosphate:creatinine ratio from Baseline to Day 28.
Time frame: Baseline and Day 28
Change in Serum Alkaline Phosphatase (ALP) From Baseline to Day 28
The effect of LEO 90100 on calcium metabolism was evaluated based on change in serum ALP from Baseline to Day 28.
Time frame: Baseline and Day 28
Change in Plasma Parathyroid Hormone (PTH) From Baseline to Day 28
The effect of LEO 90100 on calcium metabolism was evaluated based on change in plasma PTH from Baseline to Day 28.
Time frame: Baseline and Day 28
Change in Blood Pressure From Baseline to Day 28
The effect of LEO 90100 on calcium metabolism was evaluated based on vital sign assessments (blood pressure).
Time frame: Baseline and Day 28
Change in Heart Rate From Baseline to Day 28
The effect of LEO 90100 on calcium metabolism was evaluated based on vital sign assessments (heart rate).
Time frame: Baseline and Day 28
Number of Subjects Who Discontinued From the Study
Number of subjects who discontinued from the study due to adverse events.
Time frame: Baseline to Day 28
Pharmacokinetic Evaluation Cmax
The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented. All subjects but 1 had plasma concentration of calcipotriol below the LLOQ (lower limit of quantification), and thus it was not possible to calculate group mean of the derived PK parameter based on one sample. Provided values for calcipotriol Cmax are derived from that 1 subject.
Time frame: 4 weeks / 28 days
Pharmacokinetic Evaluation AUClast
The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented. All subjects but 1 had plasma concentration of calcipotriol below the LLOQ (lower limit of quantification), and thus it was not possible to calculate group mean of the derived PK parameter based on one sample. Provided values for calcipotriol AUClast are derived from that 1 subject.
Time frame: 4 weeks / 28 days
Pharmacokinetic Evaluation AUCinf
The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented.
Time frame: 4 weeks / 28 days
Pharmacokinetic Evaluation Tmax
The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented. All subjects but 1 had plasma concentration of calcipotriol below the LLOQ (lower limit of quantification), and thus it was not possible to calculate group mean of the derived PK parameter based on one sample. Provided values for calcipotriol Tmax are derived from that 1 subject.
Time frame: 4 weeks / 28 days
Pharmacokinetic Evaluation T1/2
The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented.
Time frame: 4 weeks / 28 days
Efficacy Evaluation
The percentage of subjects who achieved 'controlled disease' (i.e., Clear or Almost clear) according to the Investigator's Global Assessment (IGA) of disease severity on the trunk, limbs and scalp at Days 28 (Visit 3) and End of treatment (EoT) were presented.
Time frame: 4 weeks I 28 days and End of treatment
First Subject First Visit: 4-Jun-2012 Last Subject Last Visit: 2-May-2013
| Milestone | LEO 90100 |
|---|---|
| Started | 37 |
| Completed | 35 |
| Not completed | 2 |
HPA-axis testing by means of the rapid standard-dose cosyntropin test (ACTH-challenge test) for detection of adrenal suppression.
| Subjects | LEO 90100 |
|---|---|
| Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After Adrenocorticotrophic Hormone-challenge (ACTH-challenge) | 0 |
The effect of LEO 90100 on calcium metabolism was evaluated based on change in albumin-corrected serum calcium from Baseline to Day 28.
| mmol/L | LEO 90100 |
|---|---|
| Change in Albumin-corrected Serum Calcium From Baseline to Day 28 | 0.014 ± 0.202 |
The effect of LEO 90100 on calcium metabolism was evaluated based on change in 24-hour urinary calcium excretion from Baseline to Day 28 in 24-hour.
| mmol/24H | LEO 90100 |
|---|---|
| Change in 24-hour Urinary Calcium Excretion From Baseline to Day 28 | -0.49 ± 1.37 |
The effect of LEO 90100 on calcium metabolism was evaluated based on change in urinary calcium:creatinine ratio from Baseline to Day 28.
| mmol/g | LEO 90100 |
|---|---|
| Change in 24-hour Urinary Calcium:Creatinine Ratio From Baseline to Day 28 | -0.0300 ± 1.3997 |
Serum cortisol concentrations at 30 and 60 minutes after injection were measured in order to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration is ≤18mcg/dl at 30 minutes after the injection.
| Subjects | LEO 90100 |
|---|---|
| Number of Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 and 60 Minutes After ACTH-challenge at Day 28 | 0 |
Adverse drug reactions (ADRs) were defined as adverse events for which the investigator has not described the causal relationship to investigational medication as "not related".
| participants | LEO 90100 |
|---|---|
| Number of Participants With an Adverse Drug Reaction (ADR) | 1 |
The effect of LEO 90100 on calcium metabolism was evaluated based on change in serum phosphate from Baseline to Day 28.
| mmol/L | LEO 90100 |
|---|---|
| Change in Serum Phosphate From Baseline to Day 28 | 0.030 ± 0.145 |
The effect of LEO 90100 on calcium metabolism was evaluated based on change in 24-hour urinary phosphate excretion from Baseline to Day 28.
| mmol/24H | LEO 90100 |
|---|---|
| Change in 24-hour Urinary Phosphate Excretion From Baseline to Day 28 | -0.25 ± 8.67 |
The effect of LEO 90100 on calcium metabolism was evaluated based on change in urinary phosphate:creatinine ratio from Baseline to Day 28.
| mmol/g | LEO 90100 |
|---|---|
| Change in Urinary Phosphate: Creatinine Ratio From Baseline to Day 28 | 1.847 ± 6.215 |
The effect of LEO 90100 on calcium metabolism was evaluated based on change in serum ALP from Baseline to Day 28.
| IU/L | LEO 90100 |
|---|---|
| Change in Serum Alkaline Phosphatase (ALP) From Baseline to Day 28 | -1.5 ± 12.5 |
The effect of LEO 90100 on calcium metabolism was evaluated based on change in plasma PTH from Baseline to Day 28.
| pmol/L | LEO 90100 |
|---|---|
| Change in Plasma Parathyroid Hormone (PTH) From Baseline to Day 28 | 0.893 ± 2.207 |
The effect of LEO 90100 on calcium metabolism was evaluated based on vital sign assessments (blood pressure).
| mmHg | LEO 90100 |
|---|---|
| Diastolic Blood Pressure (mmHg) | -1.5 ± 6.2 |
| Systolic Blood Pressure (mmHg) | -2.2 ± 8.1 |
The effect of LEO 90100 on calcium metabolism was evaluated based on vital sign assessments (heart rate).
| beats/min | LEO 90100 |
|---|---|
| Change in Heart Rate From Baseline to Day 28 | 0.2 ± 10.4 |
Number of subjects who discontinued from the study due to adverse events.
| participants | LEO 90100 |
|---|---|
| Number of Subjects Who Discontinued From the Study | 0 |
The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented. All subjects but 1 had plasma concentration of calcipotriol below the LLOQ (lower limit of quantification), and thus it was not possible to calculate group mean of the derived PK parameter based on one sample. Provided values for calcipotriol Cmax are derived from that 1 subject.
| pg/ml | LEO 90100 |
|---|---|
| Betamethasone dipropionate (BDP) (n=5) | 52.2 (33.7 to 81.1) |
| betamethasone 17- propionate (n=27) | 148 (30.2 to 1133) |
| calcipotriol (n=1) | 55.9 (55.9 to 55.9) |
| MC1080 (n=5) | 24.4 (23.3 to 26.6) |
The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented. All subjects but 1 had plasma concentration of calcipotriol below the LLOQ (lower limit of quantification), and thus it was not possible to calculate group mean of the derived PK parameter based on one sample. Provided values for calcipotriol AUClast are derived from that 1 subject.
| pg/ml | LEO 90100 |
|---|---|
| Betamethasone dipropionate (BDP) (n=5) | 36.5 (16.9 to 82.5) |
| betamethasone 17- propionate (n=27) | 683.6 (18.5 to 4254) |
| calcipotriol (n=1) | 82.5 (82.5 to 82.5) |
| MC1080 (n=5) | 59.3 (55.3 to 65.5) |
The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented.
| pg/ml | LEO 90100 |
|---|---|
| Betamethasone dipropionate (BDP) (n=5) | NA (NA to NA) |
| betamethasone 17- propionate (n=27) | NA (NA to NA) |
| calcipotriol (n=1) | NA (NA to NA) |
| MC1080 (n=5) | NA (NA to NA) |
The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented. All subjects but 1 had plasma concentration of calcipotriol below the LLOQ (lower limit of quantification), and thus it was not possible to calculate group mean of the derived PK parameter based on one sample. Provided values for calcipotriol Tmax are derived from that 1 subject.
| h | LEO 90100 |
|---|---|
| Betamethasone dipropionate (BDP) (n=5) | 1.0000 (1.000 to 3.050) |
| betamethasone 17- propionate (n=27) | 2.0830 (0.00 to 7.05) |
| calcipotriol (n=1) | 2.000 (2.000 to 2.000) |
| MC1080 (n=5) | 5.0000 (3.000 to 5.000) |
The following PK parameters will be calculated, if possible, for each assayed compound based on the obtained plasma concentrations: * AUC0-t * AUC0-∞ * Cmax * Tmax * T½ If it is not possible to calculate the above PK parameters, samples with plasma concentration above lower limit of quantification (LLOQ) will be presented.
| h | LEO 90100 |
|---|---|
| Betamethasone dipropionate (BDP) (n=5) | NA (NA to NA) |
| betamethasone 17- propionate (n=27) | NA (NA to NA) |
| calcipotriol (n=1) | NA (NA to NA) |
| MC1080 (n=5) | NA (NA to NA) |
The percentage of subjects who achieved 'controlled disease' (i.e., Clear or Almost clear) according to the Investigator's Global Assessment (IGA) of disease severity on the trunk, limbs and scalp at Days 28 (Visit 3) and End of treatment (EoT) were presented.
| percentage of subjects | LEO 90100 |
|---|---|
| Day 28 (n=35) | 48.6 |
| End of treatment (n=37) | 45.9 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LEO 90100 | — | 0/37 (0%) | 4/37 (10.8%) |
| Event | LEO 90100 |
|---|---|
| Fungal infectionInfections and infestations | 1/37 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/37 |
| HeadacheNervous system disorders | 1/37 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/37 |
| Upper-airway cough syndromeRespiratory, thoracic and mediastinal disorders | 1/37 |
| ErythemaSkin and subcutaneous tissue disorders | 1/37 |
| Age, Continuous(years) | LEO 90100 |
|---|---|
| Mean | 48.0 ± 14.1 |
| Sex: Female, Male(Participants) | LEO 90100 |
|---|---|
| Female | 17 |
| Male | 20 |
Plan to share: No
The record gives a start of May 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2016, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Calcipotriene · Betamethasone dipropionate